4. Pandey R., Chander R., Sainis K.B. Prodigiosins as anti-cancer agents: living up to their name. Curr. Pharm. Des., 2009;15:732–41.

3. Montaner B., Pérez-TomásR. The prodigiosins: a new family of anticancer drugs. Curr. Cancer Drug Target, 2003;3:57– 65.

1. Wang Y., Nakajima A., Hosokawa K., et al. Cytotoxic prodigiosin family pigments from Pseudoalteromonassp. 1020R isolated from the Pacifc coast of Japan. Biosci.Biotechnol.Biochem., 2012;76:1229–32.

2. Williamson N.R., Fineran P.C., Gristwood T., et al. Anticancer and immunosuppressive properties of bacterial prodiginines. Future Microbiol., 2007;2:605–18.

5. Fürstner A., Reinecke K., Prinz H., Waldmann H. The core structures of roseophilin and the prodigiosin alkaloids defne a new class of protein tyrosine phosphatase inhibitors. ChemBioChem, 2004;5:1575–9.

6. Toomik R., Ek P. A potent and highly selective peptide substrate for protein kinase C assay. Biochem. J., 1997;322:455–60.

7. Ravi R., Jain A.J., Schulick R.D., et al. Elimination of hepatic metastases of colon cancer cells via p53-independent crosstalk between irinotecan and Apo2 Ligand/TRAIL. Cancer Res., 2004;64:9105–14.

8. Castillo-Ávila W., Abal M., Robine S., Pérez-TomásR. Non-apoptoticconcentrations of prodigiosin (H+/Cl-symporter) inhibit theacidifcation of lysosomes and induce cell cycle blockage in coloncancer cells. Life Sci., 2005;78:121–7.

9. Montaner B., Navarro S., Piqué M., et al. Prodigiosin from thesupernatant of Serratiamarcescensinduces apoptosis in haematopoietic cancer cell lines. Br. J.Pharmacol., 2000;131:585–93.

10. Soto-Cerrato V., Vinãls F., Lambert J.R., Pérez-Tomás R. Theanticancer agent prodigiosin induces p21WAF1/CIP1expression viatransforming growth factor-beta receptor pathway. Biochem.Pharmacol., 2007;74:1340–9.

11. Ju J.F., Banerjee D., Lenz H.J. et al. Restoration of wild-type p53activity in p53-null HL-60 cells confers multidrug sensitivity. Clin.Cancer Res. 1998;4:1315–22.

12. Feinstein E., Gale R.P., Reed J., Canaani E. Expression of the normalp53 gene induces differentiation of K562 cells. Oncogene, 1992;7:1853–7.

13. Yu J.L., Rak J.W., CoomberB.L.,et al. Effect of p53 status on tumorresponse to antiangiogenic therapy. Science, 2002;295:1526–8.

14. Ramoneda B.M., Pérez-TomásR. Activation of protein kinase C forprotection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem.Pharmacol., 2002;63:463–9.

15. Zhang S., Zhang Z.-Y. PTP1B as a drug target: recent developmentsin PTP1B inhibitor discovery. Drug Discov. Today, 2007;12:373–81.

16. Combs A.P. Recent advances in the discovery of competitive proteintyrosine phosphatase 1B inhibitors for the treatment of diabetes,obesity, and cancer. J. Med. Chem., 2010;53:2333–44.

17. Stuible M., Doody K.M., Tremblay M.L. PTP1B and TC-PTP: regulators of transformation and tumorigenesis. Cancer Metastasis Rev. 2008;27:215–30.